GV20 Therapeutics to Present at the Needham 23rd Annual Virtual Healthcare Conference
02 Apr 2024
Phase 1ADC
CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it will present at the Needham 23rd Annual Virtual Healthcare Conference, taking place April 8-11, 2024.
Company management will also be conducting one-on-one meetings with investors at the conference.
ABOUT GV20 THERAPEUTICS
At GV20 Therapeutics, our mission is to develop a differentiated pipeline of innovative antibody therapeutics to transform cancer treatment. We leverage our in-house STEAD platform (Simultaneous Target Evaluation and Antibody Discovery), which integrates AI, genomics, and disease biology to identify novel drug targets and create next-generation therapies against these targets. Our lead program, GV20-0251, a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting a novel innate immune checkpoint IGSF8, is in a multi-center Phase I clinical trial in patients with advanced solid tumors (NCT05669430). GV20 is headquartered in Cambridge, MA.
To learn more about GV20, please visit and follow the company on LinkedIn.
Business Contact
Ying Gong, Ph.D., CBO
BD@gv20tx.com
Investor and Media Contact
Amy Conrad
Juniper Point
amy@juniper-point.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.